Zeitschriftenartikel zum Thema „Dual inhibitors“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Dual inhibitors" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Sipos, Ádám, Eszter Szennyes, Nikolett Éva Hajnal, Sándor Kun, Katalin E. Szabó, Karen Uray, László Somsák, Tibor Docsa und Éva Bokor. „Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors“. Pharmaceuticals 14, Nr. 4 (15.04.2021): 364. http://dx.doi.org/10.3390/ph14040364.
Der volle Inhalt der QuelleGesinski, Dayna, und Sonali Kurup. „Abstract 5337: Design, synthesis and evaluation of dual-targeted mEGFR and AURK inhibitors as anticancer agents“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5337. http://dx.doi.org/10.1158/1538-7445.am2023-5337.
Der volle Inhalt der QuelleKim, Min-Jeong, Sarita Pandit und Jun-Goo Jee. „Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments“. Pharmaceuticals 15, Nr. 2 (16.02.2022): 236. http://dx.doi.org/10.3390/ph15020236.
Der volle Inhalt der QuelleBošković, Jelena, Vladimir Dobričić, Marija Mihajlović, Jelena Kotur-Stevuljević und Olivera Čudina. „Synthesis, Evaluation of Enzyme Inhibition and Redox Properties of Potential Dual COX-2 and 5-LOX Inhibitors“. Pharmaceuticals 16, Nr. 4 (06.04.2023): 549. http://dx.doi.org/10.3390/ph16040549.
Der volle Inhalt der QuelleWang, Q. May, Robert B. Johnson, Louis N. Jungheim, Jeffrey D. Cohen und Elcira C. Villarreal. „Dual Inhibition of Human Rhinovirus 2A and 3C Proteases by Homophthalimides“. Antimicrobial Agents and Chemotherapy 42, Nr. 4 (01.04.1998): 916–20. http://dx.doi.org/10.1128/aac.42.4.916.
Der volle Inhalt der QuelleLu, Haiying, Lan Bai, Yanping Zhou, Yongping Lu, Zhongliang Jiang und Jianyou Shi. „Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor“. Current Topics in Medicinal Chemistry 19, Nr. 12 (30.07.2019): 1041–50. http://dx.doi.org/10.2174/1568026619666190603092407.
Der volle Inhalt der QuelleWen, Hui, Wen Qin, Guangzhong Yang und Yanshen Guo. „Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors“. Molecules 24, Nr. 3 (30.01.2019): 497. http://dx.doi.org/10.3390/molecules24030497.
Der volle Inhalt der QuelleVest, Rebekah S., Kurtis D. Davies, Heather O'Leary, J. David Port und K. Ulrich Bayer. „Dual Mechanism of a Natural CaMKII Inhibitor“. Molecular Biology of the Cell 18, Nr. 12 (Dezember 2007): 5024–33. http://dx.doi.org/10.1091/mbc.e07-02-0185.
Der volle Inhalt der QuelleLambert, Que T., Stuart W. Ember, Muhammad Ayaz, Harshani R. Lawrence, Norbert Berndt, Steven Gunawan, Nicholas J. Lawrence, Ernst Schönbrunn und Gary W. Reuther. „Single Molecule Dual JAK2-BET Inhibition As an MPN Therapeutic“. Blood 126, Nr. 23 (03.12.2015): 2826. http://dx.doi.org/10.1182/blood.v126.23.2826.2826.
Der volle Inhalt der QuelleDyer, Richard D., und David T. Connor. „Dual Inhibitors Of Prostaglandin And Leukotriene Biosynthesis“. Current Pharmaceutical Design 3, Nr. 5 (1997): 463–72. http://dx.doi.org/10.2174/138161280305221010095741.
Der volle Inhalt der QuelleOmidkhah, Negar, und Razieh Ghodsi. „NO-HDAC dual inhibitors“. European Journal of Medicinal Chemistry 227 (Januar 2022): 113934. http://dx.doi.org/10.1016/j.ejmech.2021.113934.
Der volle Inhalt der QuelleDong, Hang, Hao Yin, Chunlong Zhao, Jiangying Cao, Wenfang Xu und Yingjie Zhang. „Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors“. Molecules 24, Nr. 13 (29.06.2019): 2407. http://dx.doi.org/10.3390/molecules24132407.
Der volle Inhalt der QuelleRogers, Brianne, Nicholas Rohde, Justin Mikitaroff, Joshua Matson, Samantha Satawa, Felix Amissah und Sonali Kurup. „Abstract 5339: 4-Amino-N-phenylbenzamides as dual-targeted mEGFR and AURK inhibitors and anticancer agents“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5339. http://dx.doi.org/10.1158/1538-7445.am2023-5339.
Der volle Inhalt der QuelleKUMAR, Priyadarsini, und Donal A. WALSH. „A dual-specificity isoform of the protein kinase inhibitor PKI produced by alternate gene splicing“. Biochemical Journal 362, Nr. 3 (08.03.2002): 533–37. http://dx.doi.org/10.1042/bj3620533.
Der volle Inhalt der QuelleMao, Beibei, Qi Zhang, Li Ma, Dong-Sheng Zhao, Pan Zhao und Peizheng Yan. „Overview of Research into mTOR Inhibitors“. Molecules 27, Nr. 16 (19.08.2022): 5295. http://dx.doi.org/10.3390/molecules27165295.
Der volle Inhalt der QuelleSun, Xuefeng, Ningning Fan, Weisi Xu, Yixing Sun, Xin Xie, Ying Guo, Liying Ma, Junyi Liu und Xiaowei Wang. „Design, synthesis and biological evaluation of caffeoyl benzanilides as dual inhibitors of HIV integrase and CCR5“. MedChemComm 7, Nr. 10 (2016): 2028–32. http://dx.doi.org/10.1039/c6md00311g.
Der volle Inhalt der QuelleCheng, Haoyang, Yanruisheng Shao und Yan Zhang. „Research Progress of PARP-1 Related Dual Target Inhibitors“. Highlights in Science, Engineering and Technology 6 (27.07.2022): 111–20. http://dx.doi.org/10.54097/hset.v6i.952.
Der volle Inhalt der QuelleHou, Xiaodan, Honghua Yan, Xin Zhang, Weidong Qian, Dong Chen, Zhihua Ren und Youzhi Tong. „Abstract 6509: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 6509. http://dx.doi.org/10.1158/1538-7445.am2024-6509.
Der volle Inhalt der QuelleWeisberg, Ellen, Lolita Banerji, Renee D. Wright, Rosemary Barrett, Arghya Ray, Daisy Moreno, Laurence Catley et al. „Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells“. Blood 111, Nr. 7 (01.04.2008): 3723–34. http://dx.doi.org/10.1182/blood-2007-09-114454.
Der volle Inhalt der QuelleUpadhayaya, Ram S., Raghava Reddy Kethiri, Avanish Vellanki, Jeff Lightfoot, Andrea Local und William G. Rice. „Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies“. Blood 128, Nr. 22 (02.12.2016): 5212. http://dx.doi.org/10.1182/blood.v128.22.5212.5212.
Der volle Inhalt der QuelleWong, Jacky, Robert Welschinger, Rana Baraz, Jocelyn Weiss, Ken Bradstock und Linda J. Bendall. „Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia“. Blood 116, Nr. 21 (19.11.2010): 3258. http://dx.doi.org/10.1182/blood.v116.21.3258.3258.
Der volle Inhalt der QuelleWong, Jacky, Robert Welschinger, Rana Baraz, Kenneth Francis Bradstock und Linda J. Bendall. „Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone.“,. Blood 118, Nr. 21 (18.11.2011): 3575. http://dx.doi.org/10.1182/blood.v118.21.3575.3575.
Der volle Inhalt der QuelleMin, Jian, Jerome C. Nwachukwu, Charles K. Min, Jacqline W. Njeri, Sathish Srinivasan, Erumbi S. Rangarajan, Charles C. Nettles et al. „Dual-mechanism estrogen receptor inhibitors“. Proceedings of the National Academy of Sciences 118, Nr. 35 (27.08.2021): e2101657118. http://dx.doi.org/10.1073/pnas.2101657118.
Der volle Inhalt der Quellevan Gijn, R., R. R. H. Lendfers, J. H. M. Schellens, A. Bult und J. H. Beijnen. „Dual topoisomerase I/II inhibitors“. Journal of Oncology Pharmacy Practice 6, Nr. 3 (01.03.2000): 92–108. http://dx.doi.org/10.1191/107815500701563317.
Der volle Inhalt der QuelleKhan, Anwar A., und Guang-Wen Zeng. „Dual Action of Respiratory Inhibitors“. Plant Physiology 77, Nr. 4 (01.04.1985): 817–23. http://dx.doi.org/10.1104/pp.77.4.817.
Der volle Inhalt der Quellevan Gijn, R., RRH Lendfers, JHM Schellens, A. Bult und JH Beijnen. „Dual topoisomerase I/II inhibitors“. Journal of Oncology Pharmacy Practice 6, Nr. 3 (September 2000): 92–108. http://dx.doi.org/10.1177/107815520000600303.
Der volle Inhalt der QuelleWoo, L. W. Lawrence, Christian Bubert, Oliver B. Sutcliffe, Andrew Smith, Surinder K. Chander, Mary F. Mahon, Atul Purohit, Michael J. Reed und Barry V. L. Potter. „Dual Aromatase−Steroid Sulfatase Inhibitors“. Journal of Medicinal Chemistry 50, Nr. 15 (Juli 2007): 3540–60. http://dx.doi.org/10.1021/jm061462b.
Der volle Inhalt der QuelleCai, Chao-Yun, Qiu-Xu Teng, Megumi Murakami, Suresh V. Ambudkar, Zhe-Sheng Chen und Vijaya L. Korlipara. „Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability“. Biomolecules 13, Nr. 2 (30.01.2023): 253. http://dx.doi.org/10.3390/biom13020253.
Der volle Inhalt der QuelleKozak, Wieslaw, Inez Archuleta, Kimberly P. Mayfield, Anna Kozak, Karin Rudolph und Matthew J. Kluger. „Inhibitors of alternative pathways of arachidonate metabolism differentially affect fever in mice“. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 275, Nr. 4 (01.10.1998): R1031—R1040. http://dx.doi.org/10.1152/ajpregu.1998.275.4.r1031.
Der volle Inhalt der QuelleKurup, Sonali, Gabe Carpenter, Samantha Satawa, Felix Amissah, Erika Lisabeth, Matthew Giletto und Edmund Ellsworth. „Abstract 4474: Novel analogs of 4-substituted pyrrolo[2,3-d]pyrimidines as dual-targeted mEGFR/AURKA inhibitors for lung cancer“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 4474. http://dx.doi.org/10.1158/1538-7445.am2024-4474.
Der volle Inhalt der QuelleWu, Yichao, Weichen Dai, Xin Chen, Aixin Geng, Yadong Chen, Tao Lu und Yong Zhu. „Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors“. RSC Advances 7, Nr. 82 (2017): 52180–86. http://dx.doi.org/10.1039/c7ra08835c.
Der volle Inhalt der QuelleChen, Xin, Shuang Zhao, Yichao Wu, Yadong Chen, Tao Lu und Yong Zhu. „Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors“. RSC Advances 6, Nr. 105 (2016): 103178–84. http://dx.doi.org/10.1039/c6ra21271a.
Der volle Inhalt der QuelleEstrada, Filipe G. A., Silvia Miccoli, Natália Aniceto, Alfonso T. Garcia-Sosa und Rita C. Guedes. „Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma“. Molecules 26, Nr. 18 (14.09.2021): 5574. http://dx.doi.org/10.3390/molecules26185574.
Der volle Inhalt der QuelleGuenther, Andreas, Renate Burger, Wolfram Klapper, Matthias Staudinger, Kathrin Richter, Tanja Ahrens und Martin Gramatzki. „Inhibitors of Mtor and PI3K Synergistically Block Plasmacytoma Cell Growth“. Blood 118, Nr. 21 (18.11.2011): 2903. http://dx.doi.org/10.1182/blood.v118.21.2903.2903.
Der volle Inhalt der QuelleKramer, Victor G., Susan M. Schader, Maureen Oliveira, Susan P. Colby-Germinario, Daniel A. Donahue, Diane N. Singhroy, Randy Tressler, Richard D. Sloan und Mark A. Wainberg. „Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load“. Antimicrobial Agents and Chemotherapy 56, Nr. 8 (21.05.2012): 4154–60. http://dx.doi.org/10.1128/aac.00409-12.
Der volle Inhalt der QuelleLeufven, Eva, und Øystein Bruserud. „Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments“. Current Medicinal Chemistry 26, Nr. 28 (25.10.2019): 5244–61. http://dx.doi.org/10.2174/0929867326666190325095853.
Der volle Inhalt der QuelleBao, Le-Quang, Daniel Baecker, Do Thi Mai Dung, Nguyen Phuong Nhung, Nguyen Thi Thuan, Phuong Linh Nguyen, Phan Thi Phuong Dung et al. „Development of Activity Rules and Chemical Fragment Design for In Silico Discovery of AChE and BACE1 Dual Inhibitors against Alzheimer’s Disease“. Molecules 28, Nr. 8 (20.04.2023): 3588. http://dx.doi.org/10.3390/molecules28083588.
Der volle Inhalt der QuelleSpinaci, Andrea, Michela Buccioni, Daniela Catarzi, Chang Cui, Vittoria Colotta, Diego Dal Ben, Eleonora Cescon et al. „“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies“. Pharmaceuticals 16, Nr. 2 (23.01.2023): 167. http://dx.doi.org/10.3390/ph16020167.
Der volle Inhalt der QuelleZhang, Lingzhi, Qiurong Ju, Jinjin Sun, Lei Huang, Shiqi Wu, Shuping Wang, Yin Li, Zhe Guan, Qihua Zhu und Yungen Xu. „Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy“. Molecules 25, Nr. 23 (03.12.2020): 5693. http://dx.doi.org/10.3390/molecules25235693.
Der volle Inhalt der QuelleBachmann, Luisa M., Maria Hanl, Felix Feller, Laura Sinatra, Andrea Schöler, Jens Pietzsch, Markus Laube und Finn K. Hansen. „Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors“. Molecules 28, Nr. 3 (20.01.2023): 1061. http://dx.doi.org/10.3390/molecules28031061.
Der volle Inhalt der QuelleŢînţaş, Mihaela-Liliana, Ludovic Peauger, Florent Alix, Cyril Papamicaël, Thierry Besson, Jana Sopková-de Oliveira Sopková-de Oliveira Santos, Vincent Gembus und Vincent Levacher. „Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core“. Molecules 28, Nr. 1 (21.12.2022): 36. http://dx.doi.org/10.3390/molecules28010036.
Der volle Inhalt der QuelleMolins, Joaquim Bellmunt, Lillian Werner, Marta Guix, Elizabeth Ann Guancial, Fabio Augusto Barros Schutz, Robert O'Brien, Edward C. Stack et al. „PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?“ Journal of Clinical Oncology 30, Nr. 15_suppl (20.05.2012): 4582. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4582.
Der volle Inhalt der QuelleWoo, L. W. Lawrence, Christian Bubert, Atul Purohit und Barry V. L. Potter. „Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity“. ACS Medicinal Chemistry Letters 2, Nr. 3 (29.12.2010): 243–47. http://dx.doi.org/10.1021/ml100273k.
Der volle Inhalt der QuelleJończyk, Jakub, Justyna Godyń, Ewelina Stawarska, Beata Morak-Młodawska, Małgorzata Jeleń, Krystian Pluta und Barbara Malawska. „Dual Action of Dipyridothiazine and Quinobenzothiazine Derivatives—Anticancer and Cholinesterase-Inhibiting Activity“. Molecules 25, Nr. 11 (03.06.2020): 2604. http://dx.doi.org/10.3390/molecules25112604.
Der volle Inhalt der QuelleMahnashi, Mater H., Sravanthi Avunoori, Sanjay Gopi, Ibrahim Ahmed Shaikh, Ahmed Saif, Farkad Bantun, Hani Saleh Faidah et al. „Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase“. PLOS ONE 19, Nr. 5 (13.05.2024): e0303173. http://dx.doi.org/10.1371/journal.pone.0303173.
Der volle Inhalt der QuelleKwon, Young-Ju, Dong Young Kim, Uk-Il Kim, Xue Meng, Ho Kyun Lee, Hyung Tae Bang, Jae-Sung Kim und Kyungjin Kim. „Abstract 491: Tankyrase-selective inhibitor STP1002 reverses resistance to MEK inhibitors in colorectal cancer with KRAS mutations“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 491. http://dx.doi.org/10.1158/1538-7445.am2023-491.
Der volle Inhalt der QuelleAl-Wahaibi, Lamya H., Hesham A. Abou-Zied, Mohamed Hisham, Eman A. M. Beshr, Bahaa G. M. Youssif, Stefan Bräse, Alaa M. Hayallah und Mohamed Abdel-Aziz. „Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways“. Molecules 28, Nr. 18 (12.09.2023): 6586. http://dx.doi.org/10.3390/molecules28186586.
Der volle Inhalt der QuelleTanabe, Kenji. „Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors“. International Journal of Molecular Sciences 18, Nr. 12 (23.11.2017): 2508. http://dx.doi.org/10.3390/ijms18122508.
Der volle Inhalt der QuelleTabrizchi, Reza. „Dual ACE and Neutral Endopeptidase Inhibitors“. Drugs 63, Nr. 20 (2003): 2185–202. http://dx.doi.org/10.2165/00003495-200363200-00003.
Der volle Inhalt der QuelleOmidkhah, Negar, Farzin Hadizadeh und Razieh Ghodsi. „Dual HDAC/BRD4 inhibitors against cancer“. Medicinal Chemistry Research 30, Nr. 10 (14.08.2021): 1822–36. http://dx.doi.org/10.1007/s00044-021-02776-9.
Der volle Inhalt der Quelle